ClearPoint Neuro, Inc. (CLPT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CLPT currently has 28.3M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 7.71% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 17, 2026 |
10-K filing | 28.3M shares outstanding |
28M | 0 |
| Jan 14, 2026 |
S-3 filing: This prospectus relates to the possible resale from time to time by the selling stockholders of up to 1,312,570 shares of common stock. |
28M | 0 |
| Nov 20, 2025 |
8-K filing: ClearPoint Neuro, Inc. completed its acquisition of IRRAS Holdings, Inc., delivering $5,000,000 in cash and 1,325,000 shares of Company common stock to IRRAS shareholders as closing consideration. |
28M | 0 |
| Nov 06, 2025 |
10-Q filing | 28.4M shares outstanding |
28M | 0 |
| Nov 06, 2025 |
8-K filing: ClearPoint Neuro, Inc. will acquire IRRAS Holdings, Inc. through a merger, with consideration including $5,000,000 in cash and 1,325,000 shares of ClearPoint Neuro common stock. |
28M | 0 |
| May 13, 2025 |
10-Q filing | 27.7M shares outstanding |
28M | 0 |
| May 12, 2025 |
8-K filing: ClearPoint Neuro, Inc. entered into a stock purchase agreement to sell 275,808 shares of common stock at $12.69 per share in a registered direct offering, with expected gross proceeds of approximately $3.5 million. ($3.5M proceeds) |
27M | 0 |
| Feb 26, 2025 |
10-K filing | 27.0M shares outstanding |
27M | 0 |
| Nov 07, 2024 |
10-Q filing | 27.6M shares outstanding |
28M | 0 |
| Aug 07, 2024 |
10-Q filing | 27.5M shares outstanding |
27M | 0 |
| May 07, 2024 |
10-Q filing | 25.5M shares outstanding |
25M | 0 |
| Mar 12, 2024 |
10-K filing | 24.6M shares outstanding |
25M | 0 |
| Mar 01, 2024 |
8-K filing: ClearPoint Neuro, Inc. entered into an underwriting agreement for a public offering of 2,307,694 shares of common stock at $6.50 per share, with an option for the underwriters to purchase an additional 346,154 shares. ($14.0M proceeds) |
25M | 0 |
| Nov 09, 2023 |
10-Q filing | 24.6M shares outstanding |
25M | 0 |
| Aug 08, 2023 |
10-Q filing | 24.6M shares outstanding |
25M | 0 |
| May 11, 2023 |
10-Q filing | 24.6M shares outstanding |
25M | 0 |
| Mar 01, 2023 |
10-K filing | 24.2M shares outstanding |
24M | 0 |
| Nov 08, 2022 |
10-Q filing | 24.5M shares outstanding |
24M | 0 |
| Aug 10, 2022 |
10-Q filing | 24.0M shares outstanding |
24M | 0 |
| May 11, 2022 |
10-Q filing | 23.7M shares outstanding |
24M | 0 |
| Mar 09, 2022 |
10-K filing | 23.7M shares outstanding |
24M | 0 |
| Nov 10, 2021 |
10-Q filing | 23.6M shares outstanding |
24M | 0 |
| Aug 12, 2021 |
10-Q filing | 22.4M shares outstanding |
22M | 0 |
| May 11, 2021 |
10-Q filing | 20.8M shares outstanding |
21M | 660K |
| Mar 22, 2021 |
10-K filing | 20.7M shares outstanding |
21M | 750K |
| Feb 19, 2021 |
8-K filing: ClearPoint Neuro, Inc. entered into an underwriting agreement for a public offering of 1,850,140 shares of common stock at $23.50 per share, with an option for the underwriters to purchase an additional 277,520 shares. ($40.6M proceeds) |
15M | 6.2M |
| Jan 22, 2021 |
S-3 filing: The filing is an S-3 shelf registration to offer common stock, preferred stock, warrants, debt securities, or units up to an aggregate amount of $120,000,000. |
15M | 6.2M |
| Nov 12, 2020 |
10-Q filing | 15.2M shares outstanding |
15M | 0 |
| Aug 13, 2020 |
10-Q filing | 15.2M shares outstanding |
15M | 0 |
| May 13, 2020 |
10-Q filing | 15.2M shares outstanding |
15M | 0 |
| Mar 27, 2020 |
10-K filing | 15.5M shares outstanding |
15M | 0 |